

## Contents

**List of Contributors** *XIII*

**Preface** *XIX*

**A Personal Foreword** *XXI*

### **Section I: Thermodynamics** *1*

#### **1 The Binding Thermodynamics of Drug Candidates** *3*

*Ernesto Freire*

##### 1.1 Affinity Optimization *3*

##### 1.2 The Binding Affinity *4*

##### 1.3 The Enthalpy Change *6*

##### 1.4 The Entropy Change *7*

##### 1.5 Engineering Binding Contributions *9*

##### 1.6 Lipophilic Efficiency and Binding Enthalpy *11*

Acknowledgments *12*

References *12*

#### **2 van't Hoff Based Thermodynamics** *15*

*Katia Varani, Stefania Gessi, Stefania Merighi, and Pier Andrea Borea*

##### 2.1 Relevance of Thermodynamics to Pharmacology *15*

##### 2.2 Affinity Constant Determination *16*

##### 2.3 The Origin of van't Hoff Equation *17*

##### 2.4 From van't Hoff toward Thermodynamic Discrimination *18*

##### 2.5 Representation of $\Delta G^\circ$ , $\Delta H^\circ$ , and $\Delta S^\circ$ Data *20*

##### 2.6 The Adenosine Receptors Binding Thermodynamics Story *21*

##### 2.7 Binding Thermodynamics of G-Protein Coupled Receptors *25*

##### 2.8 Binding Thermodynamics of Ligand-Gated Ion Channel Receptors *26*

##### 2.9 Discussion *29*

Abbreviations *31*

References *32*

<b>3</b>	<b>Computation of Drug-Binding Thermodynamics</b>	<b>37</b>
	<i>György G. Ferenczy</i>	
3.1	Introduction	37
3.2	Potential of Mean Force Calculations	39
3.3	Alchemical Transformations	41
3.4	Nonequilibrium Methods	44
3.5	MM-PBSA	44
3.6	Linear Interaction Energy	47
3.7	Scoring Functions	48
3.8	Free-energy Components	50
3.8.1	Calculation of Enthalpy	50
3.8.2	Calculation of Entropy	51
3.9	Summary	52
	References	52
<b>4</b>	<b>Thermodynamics-Guided Optimizations in Medicinal Chemistry</b>	<b>63</b>
	<i>György M. Keserü</i>	
4.1	Introduction	63
4.2	The Thermodynamics of Medicinal Chemistry Optimizations	66
4.3	Selection of Suitable Starting Points	70
4.4	Thermodynamics Based Optimization Strategies	73
	References	78
<b>5</b>	<b>From Molecular Understanding to Structure–Thermodynamic Relationships, the Case of Acetylcholine Binding Proteins</b>	<b>81</b>
	<i>Antoni R. Blaazer and Iwan J. P. de Esch</i>	
5.1	Introduction	81
5.1.1	Natural nAChR Ligands	82
5.1.2	nAChR Ligands as Therapeutic Agents	83
5.2	Acetylcholine Binding Proteins (AChBPs)	85
5.3	Thermodynamics of Small Molecule Binding at AChBPs	89
5.3.1	Thermodynamics of Natural Products Binding	90
5.3.2	Thermodynamics of Fragment Growing	94
5.4	Concluding Remarks and Outlook	98
	References	99
<b>6</b>	<b>Thermodynamics in Lead Optimization</b>	<b>107</b>
	<i>Geoffrey A. Holdgate, Andrew Scott, and Gareth Davies</i>	
6.1	Introduction to Lead Optimization in Drug Discovery	107
6.2	Measurement of Thermodynamic Parameters in Lead Optimization	111
6.2.1	Measurements of Enthalpy	112
6.2.2	Competition Experiments to Determine Affinities and Enthalpies for Tight Binding Compounds	112

6.2.3	Indirect Measurement of Enthalpy Using van't Hoff Analysis	113
6.2.4	Measurement of $k_d$ s Using Protein Thermal Unfolding	114
6.2.5	Estimation of $\Delta C_p$ of Ligand Binding	116
6.3	Advantages during Lead Optimization for Thermodynamic Measurements	117
6.4	Exploitation of Measured Thermodynamics in Lead Optimization	118
6.4.1	Enthalpic Considerations	119
6.4.2	Entropic Considerations	120
6.5	Lead Optimization beyond Affinity	120
6.5.1	Selectivity	120
6.5.2	Drug Resistance	122
6.5.3	Mechanism of Action	122
6.6	Exemplary Case Studies	123
6.6.1	Renin	123
6.6.2	Carbonic Anhydrase	124
6.6.3	HMG-CoA Reductase	125
6.6.4	HIV-1 Protease	125
6.6.5	HSP90	126
6.7	Potential Complicating Factors in Exploiting Thermodynamics in Lead Optimization	126
6.7.1	Protein Flexibility and Dynamics	126
6.7.2	The Role of Water	127
6.7.3	Linked Equilibria	128
6.7.4	Enthalpy–Entropy Compensation	129
6.7.5	Entropy–Enthalpy Transduction	131
6.8	Summary	132
	References	133
<b>7</b>	<b>Thermodynamic Profiling of Carbonic Anhydrase Inhibitors</b>	<b>137</b>
	<i>Lyn H. Jones</i>	
7.1	Introduction	137
7.2	Thermodynamic Profiles of Fragment Inhibitors	139
7.3	Thermodynamics of Fragment Growing	146
7.4	Conclusions	147
	Acknowledgments	148
	References	149
	<b>Section II: Kinetics</b>	<b>155</b>
<b>8</b>	<b>Drug–Target Residence Time</b>	<b>157</b>
	<i>Robert A. Copeland</i>	
8.1	Introduction	157
8.2	Open and Closed Systems in Biology	157

8.3	Mechanisms of Drug–Target Interactions	159
8.4	Impact of Residence Time on Cellular Activity	161
8.5	Impact on Efficacy and Duration <i>In vivo</i>	163
8.6	Limitations of Drug–Target Residence Time	166
8.7	Summary	167
	References	167
<b>9</b>	<b>Experimental Methods to Determine Binding Kinetics</b>	<b>169</b>
	<i>Georges Vauquelin, Walter Huber, and David C. Swinney</i>	
9.1	Introduction	169
9.2	Definitions	170
9.3	Experimental Strategy	171
9.4	Experimental Methodologies	172
9.4.1	Radioligand Binding	172
9.4.1.1	Kinetic Binding Properties of the Radioligand	172
9.4.1.2	Kinetic Binding Properties of the Unlabeled Drugs	173
9.4.1.3	Pros and Cons of Radiolabeled Binding	175
9.4.2	Label Free-SPR	176
9.4.2.1	General Principle of Data Acquisition	176
9.4.2.2	Kinetic Profiles for Binding to Immobilized Enzyme	177
9.4.2.3	Applications of SPR to Unravel the Kinetics of Molecular Interactions	178
9.4.2.4	Advantages of Using SPR for Kinetic Measurements	179
9.4.2.5	Disadvantages of Using SPR for Kinetic Measurements	179
9.4.3	Slow-Binding Kinetics from Enzyme Progress Curves	180
9.4.3.1	Jump Dilution Experiments	182
9.4.3.2	Pros of Measuring Binding Kinetics Using Enzyme Activity	182
9.4.3.3	Cons of Measuring Binding Kinetics Using Enzyme Activity	183
9.5	Specific Issues	183
9.5.1	Hemi-Equilibrium Conditions	183
9.5.2	Rebinding	183
9.6	Conclusion	185
	Acknowledgment	185
	References	185
<b>10</b>	<b>Challenges in the Medicinal Chemical Optimization of Binding Kinetics</b>	<b>191</b>
	<i>Michael J. Waring, Andrew G. Leach, and Duncan C. Miller</i>	
10.1	Introduction	191
10.2	Challenges	192
10.2.1	Assays and Screening Cascade	192
10.2.2	Molecular Understanding	193
10.2.3	Timescales	197
10.2.4	Molecular Properties	198
10.3	Optimization in Practice	199

10.4	Summary and Conclusions	208
	References	209
<b>11</b>	<b>Computational Approaches for Studying Drug Binding Kinetics</b>	<b>211</b>
	<i>Julia Romanowska, Daria B. Kokh, Jonathan C. Fuller, and Rebecca C. Wade</i>	
11.1	Introduction	211
11.2	Theoretical Background	211
11.2.1	Kinetics of Formation of the Diffusional Encounter Complex	213
11.2.2	Accounting for Molecular Flexibility during Diffusional Association	214
11.2.3	Modeling and Simulating the Full-Binding Process	216
11.2.3.1	Unbiased Methods	216
11.2.3.2	Biased Methods	217
11.2.4	Computing Kinetic Rate Constants from Free Energy Profiles	218
11.3	Model Types and Force Fields	218
11.3.1	All-Atom Force Fields for Proteins and Drugs	219
11.3.2	Explicit Water Models	220
11.3.3	Implicit Solvent for All-Atom Solute Representation	220
11.3.4	Coarse-Grain Models	221
11.3.5	Hybrid Force Field Models	222
11.4	Application Examples	222
11.4.1	Unbiased Molecular Dynamics Simulations	222
11.4.1.1	Understanding the Binding Process: $\beta_2$ AR	223
11.4.1.2	Calculation of $k_{\text{on}}$ Values: Src Kinase	224
11.4.1.3	Calculation of $k_{\text{off}}$ Values: FK506-Binding Protein	224
11.4.2	Enhanced Sampling Molecular Dynamics Techniques	224
11.4.2.1	Calculation of $k_{\text{on}}$ and $k_{\text{off}}$ Values: HIV-1 Protease Inhibitors	224
11.4.2.2	Relating Binding Mode to Residence Time: COX-1, COX-2	225
11.4.2.3	Understanding the Binding Process: $\beta_2$ AR and the Retinoic Acid Receptor	225
11.4.3	Brownian Dynamics	225
11.4.3.1	Calculation of $k_{\text{on}}$ Values: Influenza N1 Neuraminidase	226
11.4.3.2	Residence Times of Encounter Complexes: HSP90 and MDM2	226
11.4.3.3	Gating-Type Reactions: HIV-1 Protease	227
11.4.4	Toward Structure-Kinetic Relationships (SKRs)	227
11.5	Summary and Future Directions	228
	Acknowledgments	228
	References	229
<b>12</b>	<b>The Use of Structural Information to Understand Binding Kinetics</b>	<b>237</b>
	<i>Felix Schiele, Pelin Ayaz, and Anke Müller-Fahrnow</i>	
12.1	Introduction	237
12.2	Binding Kinetics	238

12.3	Methods to Obtain Structural Information to Understand Binding Kinetics	241
12.3.1	Indirect Methods to Identify Structural Elements That Influence the Binding Kinetics	241
12.3.2	Direct Methods to Capture Structural Information of the Transition State	242
12.3.3	Simulation Methods	242
12.4	Literature on Structure Kinetic Relationships	242
12.4.1	SKR Studies	243
12.4.2	Integration of Molecular Modeling	248
12.4.3	Molecular Features Influence Kinetics	249
12.5	Current Thinking on the Structural Factors That Influence Binding Kinetics	251
12.6	Concluding Remarks	252
	References	253
<b>13</b>	<b>Importance of Drug–Target Residence Time at G Protein-Coupled Receptors – a Case for the Adenosine Receptors</b>	<b>257</b>
	<i>Dong Guo, Adriaan P. IJzerman, and Laura H. Heitman</i>	
13.1	Introduction	257
13.2	The Adenosine Receptors	257
13.3	Mathematical Definitions of Drug–Target Residence Time	258
13.4	Current Kinetic Radioligand Assays	260
13.5	Dual-Point Competition Association Assay: a Fast and High-Throughput Kinetic Screening Method	261
13.5.1	Principle	261
13.5.2	Case Study 1: the Application Note of the Dual-Point Competition Association Assay at the A <sub>1</sub> R	263
13.5.3	Advantages of the Dual-Point Competition Association Assay and Its Future Application in Kinetic Binding Screening	267
13.6	Drug–Target Residence Time: an Often Overlooked Key Aspect for a Drug's Mechanism of Action	267
13.6.1	Case Study 2: Functional Efficacy of Adenosine A <sub>2A</sub> Receptor Agonists Is Positively Correlated to Their Receptor Residence Time	268
13.7	Conclusions	270
	Acknowledgments	271
	References	271
<b>14</b>	<b>Case Study: Angiotensin Receptor Blockers (ARBs)</b>	<b>273</b>
	<i>Georges Vauquelin</i>	
14.1	Introduction	273
14.2	Insurmountable Antagonism	275
14.2.1	Insurmountable versus Surmountable	275

14.2.2	Allosteric versus Kinetic Mechanisms	275
14.2.3	Measurement of Dissociation Rates	278
14.3	From Partial Insurmountability to an Induced Fit-Binding Mechanism	280
14.3.1	Partial Insurmountability	280
14.3.2	The “Induced Fit” Binding Model	281
14.3.3	Insurmountability and Sartan Structure	282
14.3.4	Receptor Mutagenesis and Molecular Modeling	283
14.4	Sartan Rebinding Contributes to Long-Lasting AT <sub>1</sub> -Receptor Blockade	283
14.4.1	Pharmacokinetic Considerations	283
14.4.2	Radioligand Dissociation Kinetics and Rebinding	284
14.4.3	Equations for Rebinding	286
14.4.4	Rebinding versus Allosteric Modulation	286
14.5	Summary and Final Considerations	287
	References	288
<b>15</b>	<b>The Kinetics and Thermodynamics of <i>Staphylococcus aureus</i> FabI Inhibition</b>	<b>295</b>
	<i>Andrew Chang, Kanishk Kapilashrami, Eleanor K. H. Allen, and Peter J. Tonge</i>	
15.1	Introduction	295
15.2	Fatty Acid Biosynthesis as a Novel Antibacterial Target	296
15.3	Inhibition of saFabI	297
15.4	Computer-Aided Enzyme Kinetics to Characterize saFabI Inhibition	298
15.5	Orthogonal Methods to Measure Drug–Target Residence Time	298
15.6	Mechanism-Dependent Slow-Binding Kinetics	303
15.7	Mechanistic Basis for Binary Complex Selectivity	303
15.8	Rational Design of Long Residence Time Inhibition	304
15.9	Summary	306
	References	307
	<b>Section III: Perspective</b>	<b>313</b>
<b>16</b>	<b>Thermodynamics and Binding Kinetics in Drug Discovery</b>	<b>315</b>
	<i>György M. Keserü and David C. Swinney</i>	
16.1	Introduction	315
16.2	Reaction Coordinate	316
16.3	Competing Rates	317
16.4	Thermodynamic Controlled Process – Competing Rates under Equilibrium Conditions	317
16.5	Kinetics Controlled Processes – Competing Rates under Non-equilibrium Conditions	318

16.6	Conformational Controlled Process – Kinetics as a Diagnostic for Conformational Change	319
16.7	The Value of Thermodynamics Measurements to Drug Discovery	320
16.8	Complementarity of Binding Kinetics and Thermodynamic to Discover Safer Medicines	327
	References	328
	<b>Index</b>	<b>331</b>